Effects and Underlying Mechanism of Lipid Lowering Intervention on Vascular Protection in Hypertensive Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE4

Total Enrollment

300 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-10-31

Study Completion Date

2016-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of EMINENT study is to evaluate the efficacy of Xuezhikang or atorvastatin in hypertensive patients at low/moderate cardiovascular risk.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effect of Atorvastatin and Lifestyle Intervention on Progression of Pre-Clinical Atherosclerosis

NCT00723320

Atherosclerosis

UNKNOWN NA

Atorvastatin in Pulmonary Hypertension

NCT00615823

Hypertension, Pulmonary

COMPLETED PHASE2

Further Lipid-Lowering With PCSK9 Inhibitors for Cardiovascular Outcomes in High-Risk Coronary Plaques Assessed by CT Angiography

NCT06863545

Coronary Artery Disease CT Angiography PCSK9 +1 more

RECRUITING NA

Single Dose of Atorvastatin and Circulating Endothelial Microparticles

NCT02023892

Endothelium Hydroxymethylglutaryl-CoA Reductase Inhibitors

UNKNOWN PHASE4

Effect of Atorvastatin on Carotid Intima Media Thickness

NCT04306627

Essential Hypertension Hypercholesterolemia

UNKNOWN PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

EMINENT study is to evaluate the efficacy of Xuezhikang or atorvastatin on vascular function protection in hypertensive patients at low/moderate cardiovascular risk.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hypertension

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Normal-dose statin

Lifestyle modification with Normal-dose statin

Group Type ACTIVE_COMPARATOR

Atorvastatin

Intervention Type DRUG

Atorvastatin

Lifestyle modification

Intervention Type BEHAVIORAL

Lifestyle modification

Lifestyle modification + Xuezhikang

Lifestyle changes with Xuezhikang

Group Type ACTIVE_COMPARATOR

Xuezhikang

Intervention Type DRUG

Xuezhikang

Lifestyle modification

Intervention Type BEHAVIORAL

Lifestyle modification

Group Type ACTIVE_COMPARATOR

Lifestyle modification

Intervention Type BEHAVIORAL

Lifestyle modification

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Xuezhikang

Intervention Type DRUG

Atorvastatin

Intervention Type DRUG

Lifestyle modification

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* All patients must meet the hypertension with low or moderate cardiovascular risk following 2010 Guidelines for prevention and treatment of hypertension in China

Exclusion Criteria

* Secondary Hypertension
* Women who are pregnant or lactating
* History of mental instability, or major psychiatric illness not adequately controlled and stable on therapy
* Type 2 Diabetes
* Active liver disease or impaired liver function tests
* Impaired renal function
* Uncontrolled cardiac arrhythmia
* Patient who is unable to give informed consent
* Any condition or situation, which in the opinion of the investigator, might pose a risk to the patient or confound the results of the study

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No